Document is current
Any future updates will be listed below
-
Authors
Hüzmeli, Halil https://orcid.org/0000-0002-2085-0382
Akat, Ayberk https://orcid.org/0000-0001-6592-8369
Özkara, Ahmet https://orcid.org/0000-0002-3757-3545
Ceylan, Emel https://orcid.org/0000-0001-6698-4725
Özenç, Ebru https://orcid.org/0000-0002-6720-1240
Karaöz, Erdal https://orcid.org/0000-0002-9992-833X
-
Funding
Funding for this research was provided by:
Girne American University
- License Information
-
More Information
Article History
Accepted: 26 May 2025
First Online: 12 June 2025
Declarations
:
: Mesenchymal stem cell products were obtained from the LivMedCell Good Manufacturing Practice (GMP) facility (Istanbul, Turkey). The umbilical cord tissue was collected from a single donor following informed consent, under institutional regulatory board authorization. All cell therapy applications were performed after obtaining informed consent from the patient.
: All authors confirm their full participation in the preparation and submission of the manuscript titled “Extracellular Vesicle-Enhanced Stem Cell Therapy in Acute Myocardial Infarction: A Case Report of Cardiac Regeneration from a Bypass Surgery"to the Stem Cell Reviews and Reports Journal. All authors have contributed intellectually to the manuscript, reviewed its content, and consented to its submission. The corresponding author (Ayberk Akat, Ph.D.) is authorized to communicate with the journal on behalf of all authors.
: All authors approve the final version of the manuscript for publication. They consent to the publication of relevant personal information (such as name, affiliation) in accordance with journal policies.
: The authors declare that they have no competing interests.
